Boston Scientific Corporation (NYSE:BSX) Stock Has Average Target Price of $70.19 According to Analysts

Boston Scientific Corporation (NYSE:BSX) has received an average recommendation of “Moderate Buy” from the thirty ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and twenty-three have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $70.19.

BSX has been the topic of several research reports. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, Weiss Ratings lowered Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th.

Insider Transactions at Boston Scientific

In other news, Director Edward Ludwig purchased 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Mahoney purchased 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Large investors have recently modified their holdings of the business. State Street Corp raised its holdings in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Boston Scientific during the second quarter valued at about $5,534,781,000. Capital World Investors raised its stake in Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares in the last quarter. Primecap Management Co. CA purchased a new stake in Boston Scientific in the second quarter worth about $2,156,233,000. Finally, Janus Henderson Group PLC lifted its holdings in Boston Scientific by 5.2% in the fourth quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider’s stock worth $1,200,404,000 after buying an additional 617,515 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 1.4%

BSX opened at $42.61 on Wednesday. The stock has a market cap of $61.75 billion, a PE ratio of 17.25, a P/E/G ratio of 1.04 and a beta of 0.58. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific has a 52 week low of $41.94 and a 52 week high of $105.65. The business’s fifty day simple moving average is $46.95 and its 200 day simple moving average is $51.64.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific will post 3.25 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.